110
Participants
Start Date
December 21, 2023
Primary Completion Date
April 1, 2026
Study Completion Date
November 30, 2029
AMX0035
Proprietary formulation of sodium phenylbutyrate and taurursodiol
Placebo
Matching Placebo Comparator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza, Roma
Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden
Asklepios Fachklinikum Stadtroda, Stadtroda
Hospital Clinic de Barcelona, Barcelona
Hôpital de la Timone, Marseille
Pennsylvania Hospital, Philadelphia
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milan
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan
Hospital Universitario de La Princesa, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Medical University of South Carolina (MUSC), Charleston
Hopital Caremeau, Nîmes
Groupe Hospitalier Pellegrin - Hôpital Pellegrin, Bordeaux
Augusta University, Augusta
Clinica Universidad de Navarra, Pamplona
Mayo Clinic Florida, Jacksonville
UF Health Dorothy Mangurian Neuroimaging Suite, Gainesville
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
Paracelsus-Elena-Klinik Kassel, Kassel
CHU Rennes - Hopital Pontchaillou, Rennes
Azienda Ospedale-Università di Padova, Padua
Vanderbilt University Medical Center, Nashville
Veracity Neuroscience, LLC, Memphis
Hospital Universitario Virgen del Rocio, Seville
The Cleveland Clinic Foundation, Cleveland
University of Cincinnati, Cincinnati
Hospital Universitari i Politecnic La Fe, Valencia
Quest Research Institute, Farmington Hills
Hospital de Cruces, Barakaldo
University of Minnesota, CTSI, Minneapolis
Mayo Clinic - Rochester, Rochester
Hopital Roger Salengro - CHU Lille, Lille
Northwestern University PD and Movement Disorders Center, Chicago
University of Kansas Medical Center Research Institute, Inc., Kansas City
Ochsner Medical Center, New Orleans
University of Arkansas for Medical Sciences, Little Rock
Groupe Hospitalier Pitie-Salpetriere, Paris
Kerwin Medical Center, Dallas
Baylor College of Medicine, Houston
Central Texas Neurology Consultants, Round Rock
UC Health Anschutz Outpatient Pavilion Anschutz Medical Campus, Aurora
Krankenhaus Agatharied, Hausham
University of Utah Movement Disorders Center, Salt Lake City
Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona, Salerno
Mayo Clinic, Scottsdale
CHU de Limoges - Hôpital Dupuytren, Limoges
Universitaetsklinikum Duesseldorf AoeR, Ulm
Universitaetsklinikum Ulm, Ulm
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas
University of Southern California, Los Angeles
Cedars Sinai Medical Center, Los Angeles
Parkinson's & Movement Disorder Institute, Fountain Valley
University of California, San Francisco (UCSF), San Francisco
Stanford Movement Disorder Center, Palo Alto
Parkinsons and Movement Disorder Center at the Queens Medical Center, Honolulu
Oregon Health & Science University, Portland
University of Kentucky Medical Center, Lexington
Massachusetts General Hospital, Boston
Lahey Hospital and Medical Center, Burlington
Virginia Commonwealth University Department of Neurology, Richmond
Klinikum der Universität München, Munich
Lead Sponsor
Amylyx Pharmaceuticals Inc.
INDUSTRY